Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479
(RTTNews) - Biopharmaceutical companies Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc. (NRIX) announced Monday that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX-0479.
This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies.
Under the terms, for the NX-0479 option that Gilead is exercising, Nurix will receive an option exercise payment of $20 million and potentially could receive up to an additional $425 million in clinical, regulatory, and commercial milestone payments, as well as up to low double-digit tiered royalties on product net sales.
GS-6791 is a potent, selective, oral IRAK4 degrader that targets both the scaffold and kinase functions of the IRAK4 protein kinase to block inflammatory responses downstream of toll-like receptors (TLR) and the pro-inflammatory IL1 cytokine family of receptors (IL1Rs).
IRAK4 degradation has potential applications in the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.
Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1
Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years
Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4%
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production
Gilead Sciences Says CHMP Adopts Positive Opinion To Extend Indication Of Veklury
TSX Ends Notably Higher, Gains 0.7% In Week
